Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease - PubMed (original) (raw)
Randomized Controlled Trial
Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease
Anju Nohria et al. Circ Res. 2006.
Abstract
Investigations from basic biology suggest that activation of the Rho/Rho kinase pathway reduces the bioavailability of nitric oxide (NO) and thereby promotes atherosclerosis and its clinical complications. Yet, little information is available about the relationship of the Rho/Rho kinase pathway to NO bioavailability in humans with atherosclerosis. Accordingly, we determined whether inhibition of Rho kinase augments NO bioavailability and improves endothelial function in human subjects with coronary artery disease (CAD). Thirteen CAD subjects and 16 age- and sex-matched healthy controls were randomly assigned to receive the Rho kinase inhibitor, fasudil, or placebo for 1 month each in a double-blind crossover trial. Flow-mediated, endothelium-dependent and nitroglycerin-induced, endothelium-independent vasodilation were assessed by brachial artery ultrasonography. Rho kinase activity was measured in peripheral leukocytes. Fasudil increased endothelium-dependent vasodilation in CAD subjects from 9.4+/-1.9% to 13.4+/-1.9% (P=0.001) but not in healthy controls (from 11.3+/-1.4% to 7.7+/-1.1%; P=0.07). Endothelium-independent vasodilation was not affected by fasudil in either CAD or healthy subjects. Fasudil reduced Rho kinase activity by 59+/-18% in CAD subjects (P=0.001) but not in healthy subjects (by 3+/-6%; P=0.60). The change in endothelium-dependent vasodilation achieved with fasudil relative to placebo was inversely proportional to Rho kinase inhibition (ie, greater Rho kinase inhibition was associated with larger improvement in endothelium-dependent vasodilation) (r=-0.48; P=0.01). These findings suggest that Rho/Rho kinase activation promotes endothelial dysfunction in humans with atherosclerosis. Inhibition of the Rho/Rho kinase pathway should provide a useful strategy to restore NO bioavailability in humans with atherosclerosis.
Figures
Figure 1
Study protocol.
Figure 2
Effect of fasudil on flow-mediated vasodilation. Results are expressed as mean±SE. The percentage increase in brachial artery diameter 1 minute after cuff release compared with the baseline is illustrated. Fasudil increased flow-mediated, endothelium-dependent vasodilation significantly in the CAD subjects (_P_=0.001) but not in healthy controls (_P_=0.07).
Figure 3
Effect of fasudil on nitroglycerin-mediated vasodilation. Results are expressed as mean±SE. The percentage increase in brachial artery diameter 3 minutes after sublingual nitroglycerin administration compared with baseline is illustrated. Fasudil did not significantly alter nitroglycerin-mediated, endothelium-independent vasodilation in either CAD or healthy subjects
Figure 4
Correlation of Rho kinase inhibition with fasudil and change in endothelium-dependent vasodilation. For the entire cohort of 28 patients, the change in flow-mediated, endothelium-dependent vasodilation after fasudil relative to placebo was inversely proportional to the extent of Rho kinase inhibition with fasudil (_r_=−0.48, _P_=0.01). Squares represent CAD and triangles represent healthy subjects, respectively.
Similar articles
- Long term Rho-kinase inhibition ameliorates endothelial dysfunction in LDL-Receptor deficient mice.
Steioff K, Rütten H, Busch AE, Plettenburg O, Ivashchenko Y, Löhn M. Steioff K, et al. Eur J Pharmacol. 2005 Apr 11;512(2-3):247-9. doi: 10.1016/j.ejphar.2005.03.001. Eur J Pharmacol. 2005. PMID: 15840411 - Smoking, endothelial function, and Rho-kinase in humans.
Noma K, Goto C, Nishioka K, Hara K, Kimura M, Umemura T, Jitsuiki D, Nakagawa K, Oshima T, Chayama K, Yoshizumi M, Higashi Y. Noma K, et al. Arterioscler Thromb Vasc Biol. 2005 Dec;25(12):2630-5. doi: 10.1161/01.ATV.0000189304.32725.bd. Epub 2005 Oct 6. Arterioscler Thromb Vasc Biol. 2005. PMID: 16210569 - Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension.
Fukumoto Y, Matoba T, Ito A, Tanaka H, Kishi T, Hayashidani S, Abe K, Takeshita A, Shimokawa H. Fukumoto Y, et al. Heart. 2005 Mar;91(3):391-2. doi: 10.1136/hrt.2003.029470. Heart. 2005. PMID: 15710736 Free PMC article. No abstract available. - [Basic and clinical studies on coronary vasospasm].
Hoka S, Shimokawa H. Hoka S, et al. Masui. 2002 Dec;51 Suppl:S151-7. Masui. 2002. PMID: 12655726 Review. Japanese. No abstract available. - Recent progress in the treatment of pulmonary arterial hypertension: expectation for rho-kinase inhibitors.
Fukumoto Y, Tawara S, Shimokawa H. Fukumoto Y, et al. Tohoku J Exp Med. 2007 Apr;211(4):309-20. doi: 10.1620/tjem.211.309. Tohoku J Exp Med. 2007. PMID: 17409670 Review.
Cited by
- Invasive Evaluation for Coronary Vasospasm.
Huang J, Steinberg R, Brown MJ, Rinfret S, Toleva O. Huang J, et al. US Cardiol. 2023 Jun 9;17:e07. doi: 10.15420/usc.2022.33. eCollection 2023. US Cardiol. 2023. PMID: 39493950 Free PMC article. Review. - Antiatherosclerotic effects of statins: LDL versus non-LDL effects.
Selwyn AP. Selwyn AP. Curr Atheroscler Rep. 2007 Oct;9(4):281-5. doi: 10.1007/s11883-007-0034-3. Curr Atheroscler Rep. 2007. PMID: 18173955 Review. - Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event.
Rawlings R, Nohria A, Liu PY, Donnelly J, Creager MA, Ganz P, Selwyn A, Liao JK. Rawlings R, et al. Am J Cardiol. 2009 Feb 15;103(4):437-41. doi: 10.1016/j.amjcard.2008.10.008. Epub 2008 Dec 25. Am J Cardiol. 2009. PMID: 19195498 Free PMC article. Clinical Trial. - Mechanoregulation of Vascular Endothelial Growth Factor Receptor 2 in Angiogenesis.
Miller B, Sewell-Loftin MK. Miller B, et al. Front Cardiovasc Med. 2022 Jan 11;8:804934. doi: 10.3389/fcvm.2021.804934. eCollection 2021. Front Cardiovasc Med. 2022. PMID: 35087885 Free PMC article. Review. - miR-3646 promotes vascular inflammation and augments vascular smooth muscle cell proliferation and migration in progression of coronary artery disease by directly targeting RHOH.
Kang X, Cao S, Ji Z, Zhang Y, Sun S, Shang X. Kang X, et al. Int J Clin Exp Pathol. 2018 Dec 1;11(12):5830-5839. eCollection 2018. Int J Clin Exp Pathol. 2018. PMID: 31949669 Free PMC article.
References
- Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med. 1990;323:27–36. - PubMed
- Ganz P, Vita JA. Testing endothelial vasomotor function: nitric oxide, a multipotent molecule. Circulation. 2003;108:2049–2053. - PubMed
- Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation. 2005;111:363–368. - PubMed
- Shimokawa H, Hiramori K, Iinuma H, Hosoda S, Kishida H, Osada H, Katagiri T, Yamauchi K, Yui Y, Minamino T, Nakashima M, Kato K. Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J Cardiovasc Pharmacol. 2002;40:751–761. - PubMed
- Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res. 2006;98:322–334. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 HL052233-12/HL/NHLBI NIH HHS/United States
- P01 HL048743/HL/NHLBI NIH HHS/United States
- R01 HL052233-11/HL/NHLBI NIH HHS/United States
- R01 HL070274-05/HL/NHLBI NIH HHS/United States
- P01 HL-48743/HL/NHLBI NIH HHS/United States
- R01 DK062729-05/DK/NIDDK NIH HHS/United States
- R01 HL070274-04/HL/NHLBI NIH HHS/United States
- R01 HL080187-02/HL/NHLBI NIH HHS/United States
- HL52233/HL/NHLBI NIH HHS/United States
- R01 HL052233/HL/NHLBI NIH HHS/United States
- R01 DK062729/DK/NIDDK NIH HHS/United States
- R01 HL080187-03/HL/NHLBI NIH HHS/United States
- R01 HL070274/HL/NHLBI NIH HHS/United States
- R01 HL080187/HL/NHLBI NIH HHS/United States
- R01 DK062729-04/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous